Comparison of Minimal Residual Disease as Outcome Predictor for AML Patients in First Complete Remission Undergoing Myeloablative or Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation

[1]  H. Greinix,et al.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease , 2015 .

[2]  M. Linden,et al.  Achieving stringent CR is essential before reduced-intensity conditioning allogeneic hematopoietic cell transplantation in AML , 2013, Bone Marrow Transplantation.

[3]  E. Estey,et al.  Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. , 2013, Blood.

[4]  H. Sengeløv,et al.  Long-term survival after allogeneic haematopoietic cell transplantation for AML in remission: single-centre results after TBI-based myeloablative and non-myeloablative conditioning , 2013, Bone Marrow Transplantation.

[5]  R. Porcher,et al.  Similar overall survival using sibling, unrelated donor, and cord blood grafts after reduced-intensity conditioning for older patients with acute myelogenous leukemia. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[6]  J. Gribben,et al.  Long‐term survival with low toxicity after allogeneic transplantation for acute myeloid leukaemia and myelodysplasia using non‐myeloablative conditioning without T cell depletion , 2013, British journal of haematology.

[7]  N. Kröger,et al.  Comparison of conditioning regimens of various intensities for allogeneic hematopoietic SCT using HLA-identical sibling donors in AML and MDS with <10% BM blasts: a report from EBMT , 2013, Bone Marrow Transplantation.

[8]  F. Appelbaum,et al.  Prognostic and therapeutic implications of minimal residual disease at the time of transplantation in acute leukemia , 2013, Bone Marrow Transplantation.

[9]  M. Sorror.  How I assess comorbidities before hematopoietic cell transplantation. , 2013, Blood.

[10]  E. Paietta,et al.  Minimal residual disease in acute myeloid leukemia: coming of age. , 2012, Hematology. American Society of Hematology. Education Program.

[11]  F. Baron,et al.  Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation , 2012, Leukemia.

[12]  R. Schlenk,et al.  The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach , 2012, Nature Reviews Clinical Oncology.

[13]  F. Ravandi,et al.  Monitoring minimal residual disease in acute myeloid leukemia: ready for prime time? , 2012, Journal of the National Comprehensive Cancer Network : JNCCN.

[14]  E. Copelan,et al.  Concise Review: The Role of Hematopoietic Stem Cell Transplantation in the Treatment of Acute Myeloid Leukemia , 2012, Stem cells.

[15]  Asha B. Pillai,et al.  Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia. , 2012, Blood.

[16]  B. Wood,et al.  Prognostic impact of discordant results from cytogenetics and flow cytometry in patients with acute myeloid leukemia undergoing hematopoietic cell transplantation , 2012, Cancer.

[17]  C. Dinardo,et al.  Beyond morphology: minimal residual disease detection in acute myeloid leukemia , 2012, Current opinion in hematology.

[18]  Asha B. Pillai,et al.  High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia. , 2011, Blood.

[19]  E. Estey,et al.  Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  K. Cornetta,et al.  Long-term disease-free survival after nonmyeloablative cyclophosphamide/fludarabine conditioning and related/unrelated allotransplantation for acute myeloid leukemia/myelodysplasia , 2010, Bone Marrow Transplantation.

[21]  R. Hills,et al.  Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. , 2010, Blood.

[22]  M. Maris,et al.  Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Bob Löwenberg,et al.  Review Articles (434 articles) , 2008 .

[24]  A. Rademaker,et al.  High WT1 gene expression before haematopoietic stem cell transplant in children with acute myeloid leukaemia predicts poor event‐free survival , 2009, British journal of haematology.

[25]  C. Bloomfield,et al.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.

[26]  E. Estey,et al.  Treatment of acute myeloid leukemia , 2009, Haematologica.

[27]  F. Lo Coco,et al.  Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Daniel Wolff,et al.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[29]  M. L. Beau,et al.  Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes , 2005, Bone Marrow Transplantation.

[30]  M. Sorror,et al.  Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. , 2005, Blood.

[31]  E D Thomas,et al.  1994 Consensus Conference on Acute GVHD Grading. , 1995, Bone marrow transplantation.

[32]  M. Linden,et al.  Achieving stringent CR is essential before reduced-intensity conditioning allogeneic hematopoietic cell transplantation in AML , 2013, Bone Marrow Transplantation.

[33]  M. Björkholm,et al.  The effect of allogeneic stem cell transplantation on outcome in younger acute myeloid leukemia patients with minimal residual disease detected by flow cytometry at the end of post-remission chemotherapy. , 2006, Haematologica.

[34]  M. Turner,et al.  National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.